Sprint Bioscience AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPRINT.ST research report →
Companywww.sprintbioscience.com
Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes.
- CEO
- Johan Emilsson
- IPO
- 2014
- Employees
- 38
- HQ
- Huddinge, SE
Price Chart
Valuation
- Market Cap
- $378.80M
- P/E
- 4.48
- P/S
- 2.47
- P/B
- 3.56
- EV/EBITDA
- 3.03
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 76.84%
- Op Margin
- 57.47%
- Net Margin
- 55.20%
- ROE
- 137.47%
- ROIC
- 82.77%
Growth & Income
- Revenue
- $167.17M · 154.67%
- Net Income
- $91.74M · 601.92%
- EPS
- $0.99 · 480.77%
- Op Income
- $97.33M
- FCF YoY
- 438.45%
Performance & Tape
- 52W High
- $4.21
- 52W Low
- $0.40
- 50D MA
- $2.96
- 200D MA
- $1.61
- Beta
- 0.51
- Avg Volume
- 739.60K
Get TickerSpark's AI analysis on SPRINT.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SPRINT.ST Coverage
We haven't published any research on SPRINT.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SPRINT.ST Report →